Headline Roundup
Type of Content
Approved Story
1
Format
Region
News Item Format
Standard
Image Caption
Dinendra Haria/SOPA Images/LightRocket via Getty Images
Moderna on Thursday submitted a request to the FDA for emergency use authorization for its COVID-19 vaccine in children 6 months to under 6 years of age.
Why it matters: Young children have been largely unprotected throughout the pandemic. The FDA's approval could ultimately permit them to get a COVID-19 vaccine.
The big picture: Moderna said last month its COVID-19 vaccine for children — which consists of two 25-microgram doses — generated a strong immune response in children ages 6 months to 5 years.
Efficacy was 43.7% for children ages 6 months to 2 years and 37.5% in children ages 2 to 6, clinical trial data showed.
"The majority of cases were mild, and no severe COVID-19 disease was observed in either age group," the drugmaker said last month.